LC
ATHE

Landaas & Company’s Alterity Therapeutics ATHE Stock Holding History

Landaas & Company’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-67
Closed -$1K – 80
2018
Q2 		$1K Buy
+67
New +$1.33K ﹤0.01% 335
2018
Q1 		– Sell
-67
Closed -$2K – 74
2017
Q4 		$2K Hold
67
– – ﹤0.01% 310
2017
Q3 		$2K Buy
+67
New +$1.82K ﹤0.01% 310

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
OIA
Optimum Investment Advisors Chicago, Illinois $252M AUM 26.44% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Landaas & Company's ATHE Position: Q3 2018 in Review

Landaas & Company sold out of Alterity Therapeutics (ATHE) in Q3 2018, closing a stake of 67 shares — an estimated $1K sold.

Landaas & Company first reported a position in ATHE in Q3 2017 and held it in 3 quarters. The position peaked at $2K in Q4 2017. 13 funds tracked by Wall St. Rank hold ATHE as of Q3 2018.

  • Landaas & Company reported no remaining Alterity Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Landaas & Company sold 67 Alterity Therapeutics shares in Q3 2018, an estimated $1K.
  • Landaas & Company first reported a position in Alterity Therapeutics in Q3 2017 and held it in 3 quarters.
  • Landaas & Company's Alterity Therapeutics position peaked at $2K in Q4 2017.
  • 13 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2018.

Based on Landaas & Company's 13F filing for Q3 2018, filed 14 Nov 2018.